Slideshow
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
-
Slide
This slideshow reviews cobimetinib (Cotellic), indicated for treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.